The development of a clinical test to assess the inflammatory phenotype of asthma

Completed

• Conditions: Asthma; bronchial hyperreactivity; inflammatory lung disease; 10024967

• Registration Number: NL-OMON38417
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 115

Inclusion Criteria

• Patients with adult asthma
• Age 18-75
• Visiting the outpatient clinic of the UMC and CMH Utrecht
• Suitable for sputum induction

Exclusion Criteria

• smoking at present or in the last 12 months and/or a past history of more than 10 pack years
• antibiotic treatment for a respiratory tract infection <4 weeks prior to the study
• proven allergic bronchopulmonary aspergillosis.
• Other (chronic) Inflammatory disease(s) such as rheumatoid arthritis and inflammatory bowel disease

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To investigate whether analysis of antibodies directed against active &beta;1/&beta;2-<br /><br>integrins (CD29/CD18) and Fc&gamma;RII (CD32) of primed eosinophils allows the<br /><br>diagnosis of eosinophilic asthma as compared to analysis of sputum<br /><br>eosinophilia. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Measurement of antibodies against active &beta;1/&beta;2-integrins<br /><br>and Fc&gamma;RII<br /><br>2. Measuring specific protein profiles in serum of asthma patients by<br /><br>proteomics<br /><br>3. FeNO measurement</p><br>